This article is more than 5 years old. Information may no longer be current.
Single thermal pulsation treatment provides sustained dry eye relief
Click Here to Manage Email Alerts
A single vectored thermal pulsation treatment can yield a sustained mean improvement in meibomian gland function and mean reduction in dry eye symptoms over 12 months, according to researchers in Clinical Ophthalmology.
The prospective, multicenter, open-label trial involved 200 subjects (400 eyes) who were randomized to a single vectored thermal pulsation (VTP) treatment or twice-daily, 3-month, conventional warm compress and eyelid hygiene therapy (control group).
Control group subjects received crossover VTP treatment at 3 months.
Researchers found, that at 3 months, the treatment group had greater mean improvement in meibomian gland secretion (MGS) and dry eye symptoms, compared to controls.
At 12 months, 86% of the treatment group had received only one VTP treatment and sustained a mean improvement in MGS from 6.4 ± 3.7 (baseline) to 17.3 ± 9.1 and dry eye symptoms from 44.1 ± 20.4 to 21.6 ± 21.3. In the crossover group, 89% received only one VTP treatment with sustained mean improvement in MGS from 6.3 ± 3.6 to 18.4 ± 11.1 and dry eye symptoms from 49.1 ± 21.0 to 24.0 ± 23.2, according to researchers.
The researchers noted that 86.2% of patients received no additional prescribed therapy for symptom relief during the study period.
Disclosure: Blackie is an employee of TearScience Inc., and the study was funded by TearScience. Please see the full study for all remaining authors’ relevant financial disclosures.
Click Here to Manage Email Alerts